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Abstract  
Background: Good blood management is an important determinant of outcome in 
cardiac surgery. Current guidelines recommend restrictive red blood cell (RBC) 
transfusion practice. Our objective was to systematically review the evidence from 
randomised controlled trials (RCTs) and observational studies that are used to inform 
transfusion decisions in adult cardiac surgery.  
Methods: We searched electronic databases (PUBMED, EMBASE, Cochrane Library, 
DARE) from inception to May 2015, databases from specialist societies, and 
bibliographies of included studies and recent relevant review articles. RCTs that 
evaluated the effect of liberal versus restrictive RBC transfusion threshold in cardiac and 
non-cardiac surgery patients, and observational studies that evaluated the effect of RBC 
transfusion compared with no transfusion on postoperative outcomes in adult cardiac 
surgery patients were included. Adjusted odds ratios were pooled using fixed- and 
random-effects meta-analyses.  
Findings: Data from 6 cardiac surgical RCTs (3352 patients), 19 non-cardiac surgical 
RCTs (8361 patients), and 39 observational studies (232 806 patients) were included. 
The pooled mortality odds ratios comparing liberal versus restrictive transfusion 
thresholds were 0·70 (95% CI 0.49–1·02, p=0.06) and 1·10 (95% CI 0·96-1·27, p=0.16) 
for cardiac surgical RCTs and RCTs in settings other than cardiac surgery, respectively.  
By contrast, observational cohort studies in cardiac surgery found that RBC transfusion 
compared with no transfusion was associated with substantially higher mortality (OR 
2·72; 95% CI 2·11–3·49, p<0.001) and other morbidity, although with substantial 
heterogeneity and small study effects. 
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Interpretation: Evidence from RCTs in cardiac surgery refutes findings from 
observational studies that RBC transfusion is associated with a substantially increased 
risk of mortality and morbidity. Such studies, and RCTs in non-cardiac surgery, should 
not be used to inform treatment decisions or guidelines for cardiac surgery patients.  
Funding: There was no funding source for this study. 
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Introduction 
The aim of perioperative red blood cell (RBC) transfusion in cardiac surgery is to 
improve or preserve oxygen delivery in the setting of blood loss and anaemia. The 
decision to transfuse is complicated by several factors; severe anaemia and excessive 
blood loss are common in this setting 1,2, and patients with cardiovascular disease have 
different transfusion requirements to other patient groups3. Transfusion decisions in 
cardiac surgery are most commonly based on the severity of perioperative anaemia: 
guidelines currently recommend (Grade C recommendation) highly restrictive 
transfusion thresholds with Haemoglobin (Hb) concentrations of 6-7g/dL 4,5. These are 
based largely on the results of RCTs in non-cardiac surgery patients that indicate 
equivalence for restrictive transfusion thresholds 6-8. They are also influenced by 
evidence from observational studies showing strong associations between the reversal 
of severe anaemia by RBC transfusion with adverse clinical outcomes, such as death, 
acute lung injury, acute kidney injury, stroke, myocardial infarction, sepsis, and surgical 
site infections 9-11. 
 
RBC transfusion has important morbidity; haemolytic transfusion reactions and 
Transfusion Associated Lung Injury account for a significant number of deaths per 
year12 but a causal relationship between RBC transfusion and the adverse outcomes 
suggested by observational analyses has yet to be established. Severe anaemia, the main 
indication for transfusion, is also an important predictor of adverse outcomes in cardiac 
surgery, where patients who have symptomatic cardiac disease are already at the limits 
of their physiological reserve2,11. Clinical uncertainty as to the appropriate indications 
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for transfusion is reflected in wide variations in transfusion rates in cardiac surgery; 
ranging from 25% to 95% between hospitals in contemporary cross sectional studies 13.  
 
The aims of this study were to systematically review and critically evaluate the evidence 
from RCTs and observational studies that are used to inform transfusion guidelines in 
cardiac surgery, and hence to provide evidence to support clinical transfusion decisions 
as well as to inform the design of future studies of appropriate transfusion indicators. 
 
Methods 
A protocol was developed (eAppendix pg 21) that was restricted to RCTs and 
observational studies of transfusion in cardiac surgery, but because current transfusion 
guidelines 4,5 are also based on RCTs in non-cardiac surgical patients, we subsequently 
decided to include these in this systematic review.  Despite the limitations of comparing 
different study designs, we chose to compare RCTs and observational studies as these 
are the evidence base for current guidelines. The study adhered to MOOSE (eAppendix 
pg 29) and PRISMA (eAppendix pg 31) guidelines 14,15. Two investigators (VSA, NNP) 
independently assessed studies for eligibility, risk of bias and data extraction: 
disagreements were resolved by discussion. 
 
Study Identification 
We attempted to identify all relevant published RCTs and controlled observational (non-
randomised) cohort and case-control studies evaluating the impact of RBC transfusion 
on post-operative outcomes in adult cardiac surgical patients and non-cardiac surgical 
patients (RCTs only).  We searched electronic databases (PUBMED, EMBASE, Cochrane 
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Library, DARE) from inception to May 2015. Search terms are described in the 
eAppendix pg 23. To identify RCTs in non-cardiac surgical patients, we re-ran the 
searches excluding terms relevant to the procedure (e.g. cardiac surgery) and limited 
the search to RCTs. We also searched relevant transfusion electronic databases. We 
checked the bibliographies of included studies and recent review articles for additional 
relevant articles. 
 
Study Selection 
Inclusion criteria were (1) Adult patients undergoing cardiac surgery (RCTs and 
observational studies) or critically ill/non-cardiac surgical patients (RCTs only), (2) 
Allogeneic RBC transfusion (intra- or post-operative), (3) In RCTs the comparison was 
liberal versus restrictive transfusion threshold and in observational studies the 
comparison was RBC transfusion versus no RBC transfusion. Exclusion criteria are 
provided in eAppendix pg 21. Studies evaluating the effects of storage duration on 
outcome were excluded as these compared outcomes in patients receiving “old blood” 
and “young blood”: they did not include data for patients who received “no transfusion”. 
 
Assessment of Risk of Bias 
RCTs were assessed using the Cochrane Collaboration’s Risk of Bias tool16. 
Observational studies were assessed using the Newcastle-Ottawa Scales (NOS) for 
cohort and case-control studies.  
 
Data Extraction 
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Data extraction was done independently by 2 reviewers and included author, year of 
publication, country of origin, study design, sample size, inclusion and exclusion criteria, 
methods of statistical adjustment, transfusion rate, and study results. We also noted 
variables included for statistical adjustment in observational studies, particularly 
anaemia and bleeding. Data on the transfusion of non-red cell components was not 
extracted as it was not our primary objective to explore the interaction between red cell 
and non-red cell transfusions, but to focus on the effects of red cell transfusion on 
clinically important endpoints such as death, major morbidity and resource use. 
 
Outcomes 
The primary outcome was short-term mortality. The secondary outcomes were acute 
myocardial infarction (MI), pulmonary morbidity (including adult respiratory distress 
syndrome, acute lung injury, delayed extubation), acute kidney injury (AKI) (including 
all stages of AKI, AKI requiring renal replacement therapy), infectious morbidity 
(including deep sternal wound infection, leg wound infection, sepsis), and 
cerebrovascular accident (CVA). 
 
Statistical Analysis 
Pooled odds ratios (OR) and 95% confidence intervals were estimated using both fixed- 
and random-effects meta-analyses. Where possible, we aimed to pool adjusted odds 
ratios from observational studies; otherwise we used raw outcome data to estimate 
unadjusted odds ratios.  Sensitivity analyses explored the robustness of results by 
comparing the results of fixed- and random-effects meta-analyses. We tested for and 
quantified heterogeneity using the Q and I2 statistics respectively17. Small study effects 
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were assessed by visual inspection of funnel plots and using the Egger test. The Trim 
and fill method was not used, although it was pre-specified in the protocol, as it is 
known to perform poorly in the presence of substantial between-study heterogeneity 
and we therefore concluded that it would not be appropriate to use it for these data. 
 
Analyses were stratified by study design (cardiac surgical RCT, non-cardiac surgical 
RCT, cohort studies, and case control studies) and cardiac disease state (RCTs 
exclusively recruiting patients with active cardiac disease versus those RCTs not 
recruiting patients with active cardiac disease). Differences between groups of studies 
were quantified using random-effects meta-regression. Potential explanatory variables 
considered included: study design, transfusion thresholds and number of RBC units 
transfused. In addition, we used the approach of Greenland and Longnecker 18 to 
estimate a dose-response effect in each study that provided useable data, and then 
pooled these estimates across studies. Subgroup analyses were performed by sample 
size, country, statistical adjustments, year of enrolment of first patient, and number of 
transfused RBC units. All analyses were carried out using MIX Version 2.019 and Stata 
10.0 (Statacorp, College Station, Texas). 
 
Role of Funding Source 
There was no funding source for this study. All authors had full access to all the data in 
the study and had the final responsibility for the decision to submit for publication. 
 
Results 
Characteristics of studies 
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A total of six cardiac surgical RCTs20-25 (3352 patients), 19 non-cardiac surgical RCTs 
(8361 patients) 3,6-8,26-38 and 39 cardiac surgical observational studies 9-11,39-74 (232 806 
patients) met the inclusion criteria. A flow diagram depicting the overall search strategy 
is provided in Figure 1 and characteristics of included studies are shown in the 
eAppendix pg 2. All cardiac surgical RCTs compared restrictive with liberal RBC 
transfusion strategies. Four RCTs included only low-risk surgical patients undergoing 
elective cardiac or coronary surgery and thus excluded patients at highest risk of 
requiring RBC transfusion. Only two RCTs included high risk patients defined by a CARE 
score greater than 320 or including all patients except those undergoing emergency 
procedures 25. One RCT used non-leucodepleted RBCs21 and another RCT used 
leucodepleted RBCs25. All cardiac surgical RCTs were classified as recruiting patients 
with active cardiac disease. There was no significant difference in postoperative 
bleeding between groups (eAppendix pg 7).The median number of RBC units transfused 
per patient ranged from 1 to 3.  
 
All non-cardiac surgical RCTs compared restrictive with liberal RBC transfusion 
strategies. Five RCTs evaluated outcomes in orthopaedic patients, five in critical care 
patients, three in paediatric patients, two in patients with myocardial infarction, two in 
patients with upper gastrointestinal haemorrhage, and one each in patients admitted 
because of trauma or needing vascular surgery. Nine RCTs transfused leucodepleted 
RBCs. Two RCTs exclusively recruited patients with active cardiac disease (myocardial 
infarction). 
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Among the observational studies, 21 cohort and 18 case control studies met the 
inclusion criteria. Thirty-five were retrospective studies that extracted baseline and 
outcome data from databases of routinely collected patient information. In general, 
observational studies included all patients undergoing cardiac surgery, including those 
requiring urgent or emergent surgery, impaired LV function, preoperative anaemia or 
organ dysfunction, redo surgery, and massive blood loss. All observational studies 
compared patients who did and did not receive RBC transfusion. Only one study stated 
that all RBCs administered to participants were leucodepleted45. Only 12 studies 
reported numbers of RBC units transfused: the median number per patient ranged from 
3 to 8. 
 
Risk of Bias 
The risk of bias assessment of all RCTs is shown in the eAppendix pg 8. Eighteen of 25 
studies reported adequate methods of random sequence generation and 15 studies 
reported adequate methods of allocation concealment. Most studies did not clearly 
report blinding of participants and blinding of outcome assessment. The reporting and 
handling of missing data was detailed for 22 studies. Three cardiac surgical studies 
explicitly reported adherence to a transfusion protocol. The 2 largest cardiac surgical 
RCTs were judged to be low risk for all elements of the risk of bias tool apart from 
reporting of adherence which was poorly described in one trial21,25.  
 
The quality assessment of all observational studies is shown in the eAppendix pg 9. With 
regard to cohort studies, 14 of 21 studies (67%) were assessed to be of high quality 
(NOS score higher than 6). All observational studies adjusted for common risk factors 
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associated with mortality following cardiac surgery. However, over 90% of cohort 
studies either completely or partly failed to adjust for important confounders related to 
transfusion and mortality. These include the severity of preoperative (n=11/21 studies) 
and intraoperative (n=13/21) anaemia, and bleeding (n=16/21). In case-controlled 
studies, 14 of 18 studies (78%) were assessed to be of high quality. However, all studies 
failed to adjust for at least one of the following potential confounders in their analyses: 
the severity of preoperative (n=14/18 studies) and intraoperative (n=16/18) anaemia, 
or bleeding (n=12/18)(eTable 3). None of the observational studies attempted to adjust 
for potential lead-time bias.  
 
RBC Transfusion and adverse outcomes in RCTs and observational studies 
Based on the results of five cardiac surgical RCTs, the pooled mortality odds ratio for the 
comparison liberal versus restrictive transfusion thresholds was 0·70 (95% CI 0·49-
1·02, p=0.06). There was no evidence of between-study heterogeneity (I2=0%) (Figure 
2, Table 1).  
 
By contrast, based on the results of 19 RCTs in non-cardiac surgical patients the pooled 
mortality odds ratio for the comparison liberal versus restrictive transfusion thresholds 
was 1·10 (95% CI 0·96-1·27, p=0.16). There was some evidence of between study 
heterogeneity (I2=30%)(Figure 2, Table 1). After combining all trials (cardiac and non-
cardiac surgical RCTs) there was no evidence that the risk of mortality differed between 
patients randomised to liberal or restrictive transfusion strategies (random effects OR 
1·00, 95% CI 0·82-1·21) (Figure 2). 
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To test the hypothesis that liberal transfusion thresholds may benefit patients with 
active cardiac disease, we performed a post-hoc subgroup analysis of RCTs stratified by 
active cardiac disease state. Based on a meta-analysis of seven RCTs in patients with 
active cardiac disease (five cardiac surgical trials and two trials recruiting myocardial 
infarction patients), there was evidence that liberal RBC transfusion led to a reduction in 
mortality compared with restrictive transfusion strategies (OR 0·67, 95% CI 0·47-0·95, 
p=0.03). There was little evidence of between study heterogeneity (I2=2%)(eAppendix 
pg 11). By contrast, meta-analysis of 12 RCTs recruiting patients with stable cardiac 
disease or no cardiac disease provided evidence that liberal RBC transfusion 
significantly increased mortality compared with restrictive transfusion strategies (OR 
1·17, 95% CI 1·01-1·36, p=0.04). There was moderate between study heterogeneity 
(I2=28%). A meta-regression found a significant reduction in mortality associated with 
liberal transfusion in RCTs recruiting patients with compared to without active cardiac 
disease (ratio of ORs: 0·57, 95% CI 0·36 – 0·91, p=0.02). 
 
Based on a random-effects meta-analysis of results from 16 observational cohort studies 
in cardiac surgery patients, RBC transfusion was associated on average with a 
substantial increase in mortality compared with no transfusion (random effects OR 2·72, 
95% CI 2·11 - 3·49, p<0.001, Figure 3 and Table 1). There was substantial heterogeneity 
between results of cohort studies (I2=93%), and smaller observational studies tended to 
estimate the adverse effect of RBC transfusion to be greater than did larger studies 
(Egger test P value 0·02, eAppendix pg 12), for which reason the fixed-effect estimate of 
the association between RBC transfusion and mortality was substantially attenuated 
(OR 1·63, 95% CI 1·56 – 1·70, p<0.001), compared with the random-effects estimate75. 
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There was substantial heterogeneity (I2=98%) between the associations estimated in 
three case-control studies. The association of RBC transfusion with mortality was 
significantly higher in cohort studies than was the effect of liberal compared with 
restrictive transfusion estimated in cardiac surgical RCTs (ratio of ORs: 3·11, 95% CI 
1·87 – 5·19, p<0.001). 
 
Among the six cardiac surgical RCTs there was no evidence that liberal RBC transfusion 
led to increased pulmonary morbidity compared to restrictive transfusion strategies 
(OR 0·94, 95% CI 0·76–1·17, p=0.58). There was no evidence of between-study 
heterogeneity (I2=0%) (Table 1 and eAppendix pg 13). Similarly, seven RCTs in non-
cardiac surgical patients suggested that liberal RBC transfusion did not increase 
pulmonary morbidity compared to restrictive transfusion strategies (OR 1·15, 95% CI 
0·95-1·40, p=0.14, I2=18%). By contrast, random-effects meta-analysis of results from 
seven observational studies suggested that on average RBC transfusion was associated 
with a substantial increase in pulmonary morbidity (average OR 1·99, 95% CI 1·47–
2·69, p<0.001, Table 1 and eAppendix pg 13) with evidence of significant heterogeneity 
between results (I2=97%). 
 
There was no evidence from cardiac surgical RCTs that liberal transfusion led to 
increased AKI (5 RCTs: OR 0·86, 95% CI 0·68-1·09, p=0.22) or infectious morbidity (4 
RCTs: OR 0·97, 95% CI 0·79–1·19, p=0.75) compared to restrictive transfusion 
strategies, and no evidence of between-study heterogeneity (Table 1, eAppendix pg 14 
and 15). Amongst 11 RCTs in non-cardiac surgical patients the pooled infectious 
morbidity odds ratio for the comparison liberal versus restrictive transfusion was 1·16 
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(95% CI 0·99-1·37, p=0.07, I2=0%). By contrast, random-effects meta-analysis of results 
from observational studies suggested that on average RBC transfusion was associated 
with a substantial increase in AKI (14 observational studies: OR 3·05, 95% CI 2·10-4·44, 
p<0.001) and infectious morbidity (11 observational studies: OR 2·30, 95% CI 1·85 –
2·86, p<0.001). There was substantial heterogeneity between results of observational 
studies (AKI: I2=97%; Infection: I2=73%) and smaller observational studies tended to 
estimate the adverse effect of RBC transfusion to be greater than did larger 
observational studies (AKI: Egger test P value 0·075; Infection: Egger test P value 0·037, 
eAppendix pg 16 and 17.). Correspondingly, the fixed-effect estimates of the associations 
between RBC transfusion and AKI (OR 1·73, 95% CI 1·65-1·83, p<0.001), and RBC 
transfusion and infection (OR 1·81, 95% CI 1·73-1·89, p<0.001) were substantially 
attenuated, compared with the random-effects estimates. 
 
Only 1 cardiac surgical RCT reported on MI and CVA. There was no evidence from non-
cardiac surgical RCTs that liberal transfusion led to increased MI (10 RCTs: OR 0·79, 
95% CI 0·58-1·09, p=0.15) or CVA (8 RCTs: OR 1·53, 95% CI 0·83–2·83, p=0.18) 
compared to restrictive transfusion strategies, and no evidence of between-study 
heterogeneity (Table 1, eAppendix pg 18 and 19). Random-effects meta-analysis of 
results from observational studies suggested that on average RBC transfusion was 
associated with an increase in MI (8 observational studies: OR 1·93, 95% CI 1·45-2·58, 
p<0.001) and CVA (7 observational studies: OR 2·03, 95% CI 1·42-2·90, p<0.001) with 
substantial heterogeneity between study results (MI: I2=89%; CVA: I2=79%) (Table 1, 
eAppendix pg 18 and 19). 
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Sources of Heterogeneity 
Pooled analysis of each outcome in observational studies revealed clear heterogeneity 
(Table 1). For all outcomes considered in observational studies, the heterogeneity of 
effect could not be attributed to differences in sample size, country, statistical 
adjustment or year of enrolment of first patient: when stratifying analyses by these 
variables I2 remained high (eAppendix pg 10). Exclusion sensitivity analysis did not 
reduce heterogeneity amongst observational studies (eAppendix pg 34). Important 
confounders that were not adjusted for included severity of anaemia, bleeding, and 
volume of blood transfused, all key predictors of both transfusion and adverse outcome. 
We therefore attempted to assess each of these as potential sources of heterogeneity. 
Volume of RBC transfusion was most commonly reported across studies (Table 3). For 
MI and infection, heterogeneity was substantially reduced when analyses were stratified 
according to the number of RBC units transfused. Among the 8 studies that stratified 
their analyses by the number of RBC units transfused the association of MI and infection 
with transfusion increased with the number of RBC units transfused (Table 3). Dose-
response relationships were estimable in three studies: a meta-analysis of these found 
an average increase in the odds of infection per unit of RBC administered of 1·20 (95% 
CI 1.13 – 1.28, eAppendix pg 20). Only 6 observational studies stratified their analyses 
based on preoperative or nadir haematocrit. Only 1 study adjusted for blood loss. 
Reporting of these analyses was inconsistent and therefore we were unable to conduct 
subgroup analyses based on these variables. 
 
Discussion 
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Our systematic review found that estimated effects of RBC transfusion differed markedly 
between cardiac surgical RCTs, non-cardiac surgical RCTs and observational studies. In 
RCTs of adult patients undergoing cardiac surgery, there was some evidence that a 
liberal RBC transfusion strategy reduced mortality compared with a restrictive 
transfusion strategy. There was no evidence of between-trial heterogeneity in results. 
However, fewer than 3400 patients have been randomised in such trials and only two 
included high-risk patients. In RCTs of more than 8000 non-cardiac surgical patients, 
there was little evidence that liberal transfusion reduced mortality compared to 
restrictive transfusion thresholds, and little evidence of between-trial heterogeneity in 
results. However, these trials included both adult and paediatric patients with different 
primary pathologies, as well as patients with important differences in comorbidities 
such as cardiovascular disease 8. Stratifying analyses by cardiac disease state suggested 
that liberal transfusion strategies reduce mortality in RCTs exclusively recruiting 
patients with active or symptomatic cardiac disease, such as those undergoing cardiac 
surgery or experiencing myocardial infarction. Conversely, liberal transfusion strategies 
may increase mortality in RCTs recruiting patients without active or symptomatic 
cardiac disease. 
 
By contrast with results from RCTs, observational studies of adult patients undergoing 
cardiac surgery reported substantially increased mortality, MI, pulmonary morbidity, 
AKI, CVA and infectious morbidity in those receiving RBC transfusion compared with 
those not transfused. However, there was substantial heterogeneity between the results 
of observational studies, and smaller studies tended to estimate the adverse effect of 
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RBC transfusion to be greater than larger studies. The adverse effect of RBC transfusion 
appeared to increase with increasing number of RBC units transfused. 
 
The principal explanation for the divergence in our estimates of the risks and benefits of 
red cell transfusion between observational studies and RCTs in cardiac surgery is that 
the nature of comparisons, and groups being compared, differ between these types of 
studies. RCTs directly address the question of primary clinical interest by comparing 
transfusion thresholds that reflect the variability of contemporary clinical practice. They 
are the best way to evaluate the effect of transfusion on clinical outcomes, and have the 
least risk of bias. They achieve this by comparing outcomes in groups of patients that are 
similar because of randomisation, but who receive different frequencies and volumes of 
red cell transfusion. In these trials some patients in the liberal transfusion group do not 
receive a transfusion whereas some patients in the restrictive group do receive a 
transfusion, reproducing the effect of using different thresholds in clinical settings. 
Conversely, the observational studies compared transfusion with no transfusion. This is 
problematic because the substantial risk of death and other serious adverse events 
mean that it would not be ethically justified to consider no transfusion as a treatment 
policy in patients with severe bleeding or anaemia: transfusion can be lifesaving and no 
alternatives to transfusion are available in such patients. It follows that estimated effects 
of transfusion from observational studies are likely to have been subject to unmeasured 
confounding, because they included in the transfusion group patients who became so 
severely ill during surgery that they could never have remained transfusion free. The 
TRACS and TITRE2 trial investigators clearly demonstrated the potential for such bias. 
The intention to treat comparison in both trials showed no evidence of an adverse effect 
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of a liberal transfusion strategy 21,25. However, a secondary multivariable logistic 
regression analysis of the data from both trials comparing patients who did and did not 
receive an RBC transfusion found that patients who received RBC transfusion were at 
higher risk of mortality: they were older, had higher Euroscores, longer CPB times, 
higher lactate values at the end of the operation, higher Acute Physiology and Chronic 
Health Evaluation (APACHE) II and Simplified Acute Physiology Score (SAPS) II scores 
and longer ITU and hospital stay compared to those who were not transfused 76. Even 
after adjusting for these factors, receipt of transfusion was independently associated 
with an increase in adverse outcome and this apparent adverse effect increased with 
greater transfusion volume. 
 
Two broad ways to address unmeasured confounding in observational studies could be 
considered. First, it might in principle be possible to precisely record the degree of 
morbidity present at the time of transfusion and measure such morbidity in non-
transfused patients at an equivalent time. Propensity score methods could then be used 
to identify groups of patients whose probability of transfusion was close to 1 (or close to 
zero) and exclude them from analyses 77. Second, observational analyses might mimic 
RCTs of liberal versus restrictive transfusion strategies, by following patients from the 
start of surgery and censoring those who depart from one or other strategy 78. Such an 
approach was used to address the effect on mortality of commencing antiretroviral 
therapy at different CD4 count thresholds, in HIV-1 infected patients 79. In practice, 
observational analyses of the effects of blood transfusion face considerable difficulties, 
even when appropriate analysis methods are used. For example, observational studies 
determine outcomes in patients from the time of exposure to the intervention i.e. 
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transfusion, and not the point of clinical decision making i.e. severe perioperative 
anaemia. This may produce a lead-time bias that exaggerates the effect by excluding 
clinical adverse events in patients who may have been severely anaemic, but were not 
initially transfused. In particular, it is extremely difficult to measure and control for all 
the factors influencing the decision to transfuse, since these vary during the operation 
and may be impossible to measure at times of emergency intervention. Importantly, 
none of the observational studies included in our review controlled for all the principal 
confounders, that is bleeding and anaemia. These findings lead us to question whether 
the results of existing observational studies should inform clinical transfusion decisions 
or blood management guidelines. Treatment guidelines are best informed by RCTs. 
 
In RCTs of adult patients undergoing cardiac surgery, there was evidence that a liberal 
RBC transfusion strategy reduces mortality compared with a restrictive transfusion 
strategy. This however did not reach statistical significance. These apparent differences 
therefore could have arisen by chance: relatively few patients have been randomised in 
the context of cardiac surgery. Effects of transfusion estimated in RCTs may also be 
subject to bias. Studies were not blinded and, therefore decisions about perioperative 
care may have been affected by clinicians’ knowledge of the randomised intervention 
(“performance bias”). Only three of the 6 cardiac surgical RCTs described the extent of 
adherence to the study protocol 20,21,25. If transfusion thresholds in practice were more 
similar than specified in the protocol then differences between groups may have been 
attenuated. Nonetheless it is striking that the effects in four of the five cardiac surgical 
RCTs that reported on mortality were in the direction of benefit from liberal, compared 
with restrictive, transfusion thresholds. This is in contrast to RCTs in non-cardiac 
20 
 
surgical populations, which found no difference between liberal and restrictive 
transfusion strategies but instead a trend towards increased mortality with liberal 
transfusion. A survival benefit with more liberal transfusion is plausible; patients 
undergoing cardiac surgery, who are at the limits of their cardiovascular reserve 
preoperatively, and who frequently develop oxygen supply dependency postoperatively 
may benefit from higher haemoglobin levels to improve oxygen delivery. Our post hoc 
analysis that stratified RCTs into patients with or without active cardiac disease further 
supports this hypothesis.   
 
Though subject to the limitations described above, our meta-analysis of RCTs represents 
the best available evidence that RBC transfusion may be safe (compared with available 
alternatives) in adult cardiac surgery, although the best threshold (in terms of severity 
of bleeding or anaemia) remains to be defined and may vary for different patient groups 
or stages of the perioperative journey80-82. Importantly, no RCT has shown that 
transfusion in these patients should be withheld until haemoglobin thresholds of 6-
7g/dL (except in patients with evidence of critical end-organ ischemia), as per current 
guidelines4,5.  
RBC transfusion rates range from 25-90% of patients across centres in contemporary 
studies 13,83. This is largely because appropriate indications for the use of this costly and 
valuable resource are unknown. Such uncertainty with respect to an expensive 
pharmacological intervention would be unthinkable. The results of RCTs in non-cardiac 
surgery patients may not be transferrable to a population with symptomatic cardiac 
disease and it is of concern that these, as well as the results of observational studies, 
which we have concluded are unable to guide transfusion practice, form the basis of 
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national and international blood conservation guidelines 4,5,84. Such guidelines urge 
clinicians to adopt restrictive transfusion practices due to the adverse outcomes 
demonstrated in these studies 4,5. Reduction of this uncertainty requires adequately 
powered and well conducted RCTs that anticipate the limitations that we have 
described: they should include patients at high-risk of transfusion (for example by using 
validated transfusion risk scores), and document measures taken to ensure that other 
aspects of care are the same across intervention groups, for example by blinding 
surgeons and anaesthetists to treatment allocation and allowing other staff to make 
transfusion decisions according to the study protocol. The feasibility of large trials 
enrolling high-risk patients has been demonstrated in the TITRE2 trial25 and other 
patient groups, such as gastrointestinal haemorrhage27 and high risk patients following 
hip surgery8. 
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Figure Legends 
Figure 1. Flow diagram of study selection. 
Figure 2. Forest plot of the odds of mortality in RCTs stratified according to patient 
population. 
Figure 3. Forest plot of the odds of mortality in observational studies.
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Table 1. Summary of results of meta-analyses estimating the effect of red blood cell transfusion, according to outcome and 
study design. 
 
Outcome Type of study No. of studies /  
no. of patients 
Fixed-effect 
OR (95% CI) 
Fixed-effect  
P value 
Random-effect 
OR (95% CI) 
Random-effect  
P value 
I2(%) Heterogeneity 
P value 
Egger test 
P value 
Mortality 
Cardiac Surgical RCT 5/3304 0.70 (0.49–1.02) 0.06 0.70 (0.49–1.02) 0.06 0 0.46 0.80 
Non-Cardiac Surgical RCT 19/8341 1.10 (0.96–1.27) 0.16 1.07 (0.88–1.31) 0.49 29.7 0.11 0.41 
Observational 19/138357 1.48 (1.42–1.53) <0.001 2.81 (2.21–3.56) <0.001 95.4 <0.001 0.02 
Pulmonary 
Cardiac Surgical RCT 6/3357 0.94 (0.76–1.17) 0.58 0.94 (0.76–1.17) 0.58 0 0.51 0.66 
Non-Cardiac Surgical RCT 7/4944 1.15 (0.95–1.40) 0.14 1.15 (0.91–1.44) 0.25 17.6 0.30 0.90 
Observational 7/43431 1.68 (1.63–1.74) <0.001 1.99 (1.47–2.69) <0.001 97.0 <0.001 0.74 
AKI 
Cardiac Surgical RCT 5/3304 0.86 (0.68–1.09) 0.22 0.86 (0.68–1.09) 0.22 0 0.83 0.75 
Non-Cardiac Surgical RCT 2/1119 1.27 (0.95–1.69) 0.10 1.27 (0.95–1.69) 0.10 0 0.73 - 
Observational 14/59003 1.73 (1.65–1.83) <0.001 3.06 (2.10–4.46) <0.001 97.0 <0.001 0.08 
Infection 
Cardiac Surgical RCT 4/2802 0.97 (0.79–1.19) 0.75 0.97 (0.79–1.19) 0.75 0 0.69 0.21 
Non-Cardiac Surgical RCT 11/6225 1.16 (0.99–1.37) 0.07 1.16 (0.99–1.37) 0.07 0 0.45 0.48 
Observational 11/88025 1.81 (1.73–1.89) <0.001 2.30 (1.85–2.86) <0.001 72.9 <0.001 0.04 
MI Cardiac Surgical RCT 1/2003 1.34 (0.30- 6.02) 0.70 1.34 (0.30- 6.02) 0.70 - - - 
Non-Cardiac Surgical RCT 10/5539 0.79 (0.58–1.09) 0.15 0.88 (0.56–1.37) 0.57 25.8 0.21 0.11 
Observational 8/35763 1.55 (1.48–1.62) <0.001 1.93 (1.45–2.58) <0.001 89.1 <0.001 0.38 
CVA Cardiac Surgical RCT 1/2003 1.14 (0.57- 2.30) 0.71 1.14 (0.57- 2.30) 0.71 - - - 
Non-Cardiac Surgical RCT 8/3648 1.53 (0.83–2.83) 0.18 1.53 (0.83–2.83) 0.18 0 0.71 0.35 
Observational 7/43649 1.41 (1.34–1.48) <0.001 2.03 (1.42–2.90) <0.001 79.4 <0.001 0.08 
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Table 2. Summary of meta-analyses in observational studies estimating the effect of red blood cell transfusion in adult cardiac 
surgery, stratified according to the quantity of RBC units transfused. 
 
Outcome No. of RBC Units No. of studies Random-effects 
OR (95% CI) 
I2(%) Heterogeneity 
P value 
Mortality 
1-2 units 1 2.97 (0.96–9.20) - - 
3-6 units 1 5.82 (1.30–26.04) - - 
>6 units 3 3.84 (1.69–8.74) 43 0.17 
Pulmonary 
1-2 units - - - - 
3-6 units - - - - 
>6 units - - - - 
AKI 
1-2 units 2 3.45 (1.92–6.20) 86 0.01 
3-6 units 2 6.74 (3.68–12.33) 90 0.01 
>6 units 3 3.42 (2.35–4.97) 95 <0.001 
Infection 
1-2 units 4 1.73 (1.34–2.25) 0 0.64 
3-6 units 4 2.68 (1.49–4.82) 67 0.03 
>6 units 4 5.50 (2.62–11.53) 71 0.02 
MI 1-2 units 2 2.22 (1.74 – 2.82) 62 0.11 
3-6 units 2 4.87 (3.80 – 6.24) 0 0.62 
>6 units 2 9.66 (7.49 – 12.46) 11 0.29 
CVA 1-2 units - - - - 
3-6 units - - - - 
>6 units - - - - 
 
 
